More than 400 million people worldwide have been infected with hepatitis B virus (HBV) and are at risk of end-stage liver diseases such as liver cirrhosis,liver failure and hepatocellular carcinoma (HCC).Current therapeutics for chronic hepatitis B (CHB) are limited to nucleoside analogues (NAs) and interferon-α(IFN-α);these drugs reduce viral load,improve long-term outcome,but rarely lead to a cure of CHB [1].